MedPath

Effects of Platelet-rich Plasma in the Surgery of Carpal Tunnel Syndrome: A Randomized Controlled Trial

Not Applicable
Completed
Conditions
Carpal Tunnel Syndrome
Interventions
Procedure: Platelet-rich plasma
Procedure: Platelet-poor plasma
Registration Number
NCT03548259
Lead Sponsor
Cardenal Herrera University
Brief Summary

The Platelet-rich plasma (PRP) has been proved to be efficient in the non-surgical treatment of carpal tunnel syndrome (CTS). Here we propose to assess the effectiveness of PRP as co-adjuvant in surgical treatment of CTS by open carpal tunnel release.

Design: Randomized Controlled Trial. Setting: Local Hospital.

Detailed Description

Carpal tunnel syndrome (CTS) is a common disorder with an estimated annual incidence of 125-542 in adults, and an estimated prevalence of 1 to 5 percent in the general population. CTS is the most frequent compressive focal mononeuropathy and causes pain, paresthesia and weakness of the median nerve distribution in patients.

The treatment of the CTS includes both, conservative and surgical treatment depending on the severity of the symptoms.

Platelet-rich plasma (PRP) has been proved to be efficient in the non-surgical treatment of CTS, however its potential used as co-adjuvant in surgical treatment has not been assessed.

We propose a randomized clinical trial in patients in which the surgical treatment is indicated. Participants in the intervention group receive a PRP injection, and in the control group a platelet-poor plasma injection after open carpal tunnel release. The evaluation is performed pretreatment as well as on the 6st week after treatment. Outcome measures include: hand grip strength (primary outcome), pain, sympton severity and functional status.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Patients with Carpal Tunnel Syndrome (CTS)
  • Conservative treatment failure
Exclusion Criteria
  • Previous CTS surgery on the same side
  • Wrist fracture/trauma in history
  • Polyneuropathy
  • Diabetes mellitus
  • Cervical neuropathy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ExperimentalPlatelet-rich plasmaPlatelet-rich plasma
ExperimentalPlatelet-poor plasmaPlatelet-rich plasma
Platelet-poor plasmaPlatelet-rich plasmaPlatelet-poor plasma
Platelet-poor plasmaPlatelet-poor plasmaPlatelet-poor plasma
Primary Outcome Measures
NameTimeMethod
Hand grip strength6 weeks

Hand grip strength measured with dynamometer

Secondary Outcome Measures
NameTimeMethod
Functional status6 weeks

Functional status measured with the sympton severity scale of the Boston Carpal Tunnel Syndrome Questionnaire.The Functional Status Scale (FSS) contains 8 items and uses a five-point rating scale that generates a final score (sum of individual scores divided by number of items) which ranges from 1 to 5, with a higher score indicating greater disability.

Pain6 weeks

Pain measured with the Wong-Baker Faces Pain Rating Scale. The scale shows a series of faces ranging from a happy face at 0 which represents "no hurt" to a crying face at 10 which represents "hurts worst".

Sympton severity6 weeks

Sympton severity measured with the sympton severity scale of the Boston Carpal Tunnel Syndrome Questionnaire. The Symptom Severity Scale (SSS) contains 11 questions and uses a five-point rating scale that generates a final score (sum of individual scores divided by number of items) which ranges from 1 to 5, with a higher score indicating greater disability.

Wound healing6 weeks

Wound healing measured with the Southampton Wound Assessment Scale. Wounds are scored as 0, I, II, III, IV and V, with a higher score indicating worst healing.

Trial Locations

Locations (1)

Universidad CEU Cardenal Herrera

🇪🇸

Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath